OligomicsTx develops RNA-targeting therapies, specifically next-generation Antisense Oligonucleotides (ASOs), for rare neuromuscular disorders like FOP, FSHD, DMD, and SMA. Their approach combines advanced ASOs with novel delivery mechanisms to improve tissue targeting and reduce off-target toxicity, aiming to enhance treatment potency for these genetic conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many rare neuromuscular disorders, such as Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Spinal Muscular Atrophy (SMA), and Fibrodysplasia Ossificans Progressiva (FOP), lack effective treatments. Existing therapies often have limited efficacy, off-target effects, or require invasive administration. These diseases cause progressive muscle weakness, loss of motor function, and reduced quality of life for affected individuals.
Solution
OligomicsTx is developing next-generation RNA-targeting therapies using antisense oligonucleotides (ASOs) to address the unmet needs in rare neuromuscular diseases. Their approach combines target-optimized ASOs and gapmers with novel delivery technologies to improve tissue targeting, penetration, and efficacy while reducing toxicity. These ASO+delivery combinations can modulate gene expression, either increasing or decreasing protein production, to restore muscle function and prevent disease progression. The company's therapies aim to provide improved systemic delivery and target specificity compared to existing treatments.
Target Audience
OligomicsTx's primary target audience includes patients suffering from rare neuromuscular disorders such as DMD, FSHD, SMA, and FOP, as well as the clinicians and healthcare providers who treat them.
Features
- Target-optimized ASOs and gapmers designed for specific neuromuscular disease targets
- Novel delivery technologies to enhance tissue penetration and reduce off-target effects
- ASO+delivery combinations capable of triggering gene 'knock up' and 'knock down'
- Preclinical data demonstrating improved muscle function in DMD models, with significant dystrophin restoration and prevention of cardiac damage
- ASO+LNP combination in development for FSHD, showing improved muscle fusion and reduced DUX4 expression in preclinical studies
- Improved SMN levels and muscle function in SMA preclinical models, with no apparent immune response or toxicity
- RNA-based therapy for FOP targeting the mutated ACVR1 gene, demonstrating improved exercise performance, survival, and prevention of extra bone formation in preclinical studies